NASDAQ:DTIL
Precision BioSciences Inc. Stock News
$13.00
-0.0800 (-0.612%)
At Close: May 23, 2024
Tiziana Life Sciences surges on exclusive licensing agreement with Precision BioSciences
06:53am, Thursday, 02'nd Sep 2021
Tiziana Life Sciences PLC surged 19% to 73p after signing an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL). The pair will explore the use of Tiziana's foralumab monoclonal ant
Tiziana Life Sciences inks exclusive licensing deal with US group Precision BioSciences that takes it into CAR-T therapy
02:55am, Thursday, 02'nd Sep 2021
Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) said it has inked an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL) to explore the use of Tiziana's foralumab monoclonal antib
Precision BioSciences: The Right Profile To Progress
09:26am, Friday, 27'th Aug 2021
Precision uses its ARCUS genome editing method to overcome cancers and cure genetic diseases. This is different from CRISPR, another gene editing technology which has recently been the subject of an a
Precision BioSciences: Q2 Earnings Insights
07:38am, Thursday, 12'th Aug 2021
Shares of Precision BioSciences (NASDAQ:DTIL) rose 0.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 157.14% year over year to $0.36, which be
Precision BioSciences (DTIL) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
04:44pm, Thursday, 05'th Aug 2021
Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Precision BioSciences Starts Dosing In Blood Cancer Trial With CAR T Therapy
01:41pm, Thursday, 01'st Jul 2021
Precision BioSciences Inc (NASDAQ: DTIL) has dosed the first patient in its Phase 1 trial with PBCAR19B in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) PBCAR19B is an immune-e
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® gen
Precision BioSciences (DTIL) Surges 6.6%: Is This an Indication of Further Gains?
09:54am, Tuesday, 29'th Jun 2021
Precision BioSciences (DTIL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price
DTIL Stock Price Increased Over 6%: Why It Happened
04:01pm, Monday, 28'th Jun 2021
The stock price of Precision BioSciences Inc (NASDAQ: DTIL) increased by over 6%. This is why it happened.
Precision BioSciences Moves Higher After Commencing Dosing In PBCAR269A Combination Arm Of Multiple Myeloma Trial
09:16am, Monday, 28'th Jun 2021
Precision BioSciences Inc (NASDAQ: DTIL) and SpringWorks Therapeutics Inc (NASDAQ: SWTX) have dosed the first patient in the combination arm of Precision's Phase 1/2a trial evaluating PBCAR269A.�
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® geno
Precision BioSciences' CD-19 CAR T Therapy Shows Response Rate Of 77% In Lymphoma Trial
01:54pm, Thursday, 20'th May 2021
Precision BioSciences Inc (NASDAQ: DTIL) announced additional data from its Phase 1/2a study evaluating PBCAR0191, off-the-shelf, allogeneic CAR T candidate targeting CD19. Data will be presented a
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates
12:55pm, Thursday, 13'th May 2021
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 32.65% and 86.51%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
DTIL Stock: Over 10% Increase Intraday Explanation
03:11pm, Tuesday, 11'th May 2021
The stock price of Precision BioSciences Inc (NASDAQ: DTIL) increased by over 10% during intraday trading. This is why it happened.
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, announced today tha